COVID-19 Vaccines – What Older Canadians Need to Know



October 2023 (Updated January 2024)







National Institute on Ageing



Suggested Citation:

Sinha, S. K., Arulnamby, A., Vohra-Miller, S., & Johnstone, J. (2024). COVID-19 Vaccines – What Older Canadians Need to Know. National Institute on Ageing. Toronto, ON.

Mailing Address:

National Institute on Ageing
Ted Rogers School of
Management
350 Victoria St.
Toronto, Ontario
M5B 2K3
Canada

About the National Institute on Ageing

The National Institute on Ageing (NIA) is a public policy and research centre based at Toronto Metropolitan University (formerly Ryerson University). The NIA is dedicated to enhancing successful ageing across the life course. It is unique in its mandate to consider ageing issues from a broad range of perspectives, including those of financial, psychological, and social wellbeing.

The NIA is focused on leading cross-disciplinary, evidence-based, and actionable research to provide a blueprint for better public policy and practices needed to address the multiple challenges and opportunities presented by Canada's ageing population.

The NIA is committed to providing national leadership and public education to productively and collaboratively work with all levels of government, private and public sector partners, academic institutions, ageing related organizations, and Canadians.

About UHN and Sinai Health's Healthy Ageing and Geriatrics Program

Sinai Health and University Health
Network's Healthy Ageing and Geriatrics
Program is dedicated to the care of all
older persons, particularly the complex
and frail. We provide interpersonal
expertise, conduct research, implement
innovative models of care, educate
ourselves and others, and collaborate with
all partners to enable healthy ageing.

Authors

This guidance document was written by:

Dr. Samir K. Sinha, MD, DPhil, FRCPC, FCAHS, AGSF

Director of Geriatrics
Sinai Health and University Health Network;
Director of Health Policy Research,
National Institute on Ageing;
Associate Professor, Departments of Medicine,
Family and Community Medicine, Health Policy,
Management and Evaluation,
University of Toronto

Arushan Arulnamby, MPH

Policy Analyst, National Institute on Ageing, Toronto Metropolitan University

Ms. Sabina Vohra-Miller, MSc

Founder of Unambiguous Science

Dr. Jennie Johnstone, MD, PhD, FRCPC

Medical Director, Infection Prevention and Control, Sinai Health; Infectious Diseases Departmental Division Director, University of Toronto; Associate Professor, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto



Table of Contents

General Questions on COVID-19 Vaccines	7
Questions Specific to Older Adults	13
Questions for Specific Population Groups	18
Debunking Myths About COVID-19 Vaccines	22
Other Questions	24



Introduction

Since late 2020, there have been various COVID-19 vaccines that have been developed, approved and recommended in Canada based on research and epidemiological reports. News of these COVID-19 vaccines being developed and approved have been met with excitement and hope, but also some skepticism, particularly among older adults and some of the most vulnerable members of our society.

There are many legitimate questions and misconceptions out there about COVID-19 vaccines, how they came to be and what they mean for our personal health. It is important to address these concerns as Canada moves away from a crisis phase and progresses towards the long-term management of COVID-19.

Here are some common questions arising about COVID-19 vaccines among older Canadians along with evidence-informed answers to help keep you up to date with the facts.



General Questions on COVID-19 Vaccines

How do vaccines work?

Our body may come across various bacteria, viruses or fungi that can cause diseases. These are known as pathogens. To fight off these disease-causing organisms, our body's immune system develops antibodies that are produced based on a part of the pathogen called an antigen. This helps create protection against the disease, which is known as immunity. In our body, we have thousands of different antibodies for specific pathogen-related antigens.

When our body encounters a new pathogen, like the COVID-19 virus, it will take time to produce the specific antibodies. By the time our body is ready to fight back, the infection can already have caused a lot of damage that can sometimes lead to severe illness and death. But once it fights off that virus, our body also creates antibody-producing memory cells that helps it remember how to fight off that particular virus. Therefore, the next time you come into contact with the same virus, your body remembers it and is able to quickly assemble its defence system against it.

This is where vaccines can be advantageous. Vaccines contain weakened virus, inactive antigens or a blueprint to produce antigens that triggers an immune system response. They allow the body

to ramp up an immune response against a variety of pathogens. This means that later, if your body comes across an actual pathogen you have been immunized against, it can quickly recognize and respond to it immediately, and fight it off before it causes serious health issues.

How do mRNA vaccines work and which ones are available?

mRNA or messenger RNA, is a naturally occurring molecule in our bodies and gives instructions to our bodies to make necessary proteins, similar to a recipe card.

Prior to the COVID-19 pandemic, researchers had been studying and working with mRNA-based treatments for decades. As soon as the necessary information about the virus that causes COVID-19 was available, scientists began designing the first mRNA COVID-19 vaccines.

In these vaccines, synthetic mRNA is used to tell the body to make a harmless piece of the spike protein antigen that is found on the surface of the actual COVID-19 virus. These vaccines work by delivering mRNA instructions or a recipe card that directs the body to produce a small amount of the spike protein antigen. Our body recognizes that this antigen doesn't belong and ramps up an

immune response by producing protective antibodies against the COVID-19 virus' spike protein antigen, so if our body later comes in contact with an actual COVID-19 causing virus, it immediately knows how to fight it off. The mRNA in the vaccine does not last long in the body as it quickly gets broken down. The mRNA from the vaccine cannot get into your DNA or alter it in any way.

mRNA vaccines are an exciting scientific advance and will allow us to design vaccines for other viruses as well, such as influenza, respiratory syncytial virus (RSV), Zika, rabies and cytomegalovirus (commonly known as CMV). mRNA vaccines are also being studied as a novel way to fight cancer.

There have been various mRNA COVID-19 vaccines approved in Canada for adults, targeting different variants of the SARS-COV-2 virus. Of the mRNA vaccines that have been approved over the past three years, only the two new mRNA vaccines that have been approved for use in fall 2023 to target one of the more recent virus strains: Comirnaty® Omicron XBB.1.5 (Pfizer-BioNTech) and Spikevax® XBB.1.5 (Moderna) are currently available.

How do protein subunit vaccines work and which ones are available?

Protein subunit vaccines have been used for several decades for the protection against various diseases including pertussis and hepatitis B. These vaccines contain purified proteins of the virus that are developed through a well-established process. First, a piece of the virus's genetic material that holds instructions to develop the COVID-19 virus' spike protein is inserted into another cell, allowing the production of the protein. The protein is then purified and inserted into the body to trigger an immune response. To enhance the immune response of the protein antigen, the vaccine also includes the adjuvant Matrix-M. Adjuvants have been used safely across various vaccines.

Protein subunit vaccines are not able to cause infection as it does not contain the virus.

The **Nuvaxovid™** (Novavax) COVID-19 vaccine was the only protein subunit COVID-19 vaccine available for adults in Canada. The **Nuvaxovid™ XBB.1.5** (Novavax) COVID-19 vaccine has also been approved for use in December 2023 to target one of the more recent virus strains.

What is the difference between a primary series and the additional doses?

A primary series are the initial dose(s) an individual receives of the COVID-19 vaccines. This can vary from one to two doses. The recommended interval between two doses of COVID-19 vaccine for a primary series is eight weeks.

It is currently recommended that mRNA vaccines be used for a primary series. If these are not available, the protein subunit COVID-19 vaccine **Nuvaxovid**TM (Novavax) should be offered. It is important to note that different vaccines can be used to complete a primary series.

The reason additional doses are recommended after the primary series is to increase people's protection against COVID-19 infection and COVID-19 symptomatic and severe disease that has likely waned since their last vaccination or infection. It is recommended to be given at least six months from the last COVID-19 vaccination or infection. Even though a shorter interval (e.g., three months to <six months) has not been shown to pose a safety risk, a longer interval ensures a higher level of immunity or protection is reached over time.

Similar to a primary series, mRNA COVID-19 vaccines are the preferred vaccine to be given as additional doses. If mRNA COVID-19 vaccines are not available, the protein subunit COVID-19 vaccine **Nuvaxovid**™ (Novavax) should be offered.

The December 2023 approved

Nuvaxovid™ XBB.1.5 (Novavax) is
currently under review by Canada's

National Advisory Committee on
Immunization (NACI) so that they can
provide further guidance on how to best
use this vaccine.

What are the newest formulations of COVID-19 vaccines?

Currently, there are newer Omicron strains that are more prevalent in Canada compared to what was targeted by previously available COVID-19 vaccines. These new Omicron strains are able to better avoid antibodies from the body compared to previous Omicron strains.

Since the fall of 2023, a new set of COVID-19 vaccines have become available in Canada that specifically target one of the more recent Omicron strains. These vaccines do not include the original strain of the SARS-CoV-2 virus, and instead only comprise one of the newer Omicron strains. As a result, they are expected to provide a better immune response in comparison to previously available COVID-19 vaccines. For this reason, NACI has recommended that individuals receive the XBB.1.5-containing mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech), regardless of the number of vaccine doses they have previously received. The time interval for vaccination, depends on previous COVID-19 vaccine and/or infection history (please see page 13 for recommendations for older adults).

The Comirnaty® Omicron XBB.1.5
(Pfizer-BioNTech) and Spikevax® XBB.1.5
(Moderna) were approved for use by
Health Canada in September 2023.

A new formulation of COVID-19 vaccine by Novavax has also been approved for use by Health Canada in December 2023. This new vaccine is currently under review by NACI so that they can provide further guidance on how to best use this vaccine.

Already, data from animal and/or human trials have demonstrated that the new Moderna, Novavax and Pfizer-BioNTech vaccines developed robust immune responses against SARS-CoV-2 XBB*
Omicron virus strains.

COVID-19 vaccines have been developed very fast.
Have important steps been skipped in their development?

According to the Health Canada's <u>website</u>, all of Canada's approved COVID-19 vaccines have:

- met the normal requirements for a vaccine's approval, including all of the usual safety, quality and efficacy requirements for vaccines, and no requirements were overlooked in order to approve the use of these vaccines; and
- their quality, safety and effectiveness monitored on an ongoing basis.

Countries and companies across the world have banded together and collaborated in a way we haven't seen in the past to help develop COVID-19 vaccines. Health agencies and vaccine researchers and manufacturers have prioritized the development of COVID-19 vaccines by investing huge sums of money, redeploying staff and developing several collaborations to work on COVID-19 vaccine-related efforts. None of this occurred at the expense of safety, and due diligence was absolutely done in the clinical trials that were required to demonstrate both their safety and efficacy.

Other factors that accelerated the creation of the approved COVID-19 vaccines include:

■ The development of our earliest COVID-19 vaccines were based on decades of research that were conducted on other strains of coronavirus prior to COVID-19, such as Middle East Respiratory Syndrome (MERS) and SARS-CoV (SARS).



- Additional advances in science and technology made the development of new vaccines easier; once the virus was genetically sequenced, which occurred soon after the COVID-19 virus was discovered, scientists could quickly get to work to create a variety of vaccine candidates and start clinical trials.
- Strong international collaboration among scientists, health professionals, researchers, industry and governments, including ample funding to implement the large clinical trials needed to more quickly test and establish the safety and effectiveness of the vaccines being developed.

Should people take acetaminophen (also known as Tylenol) or non-steroidal anti-inflammatory drugs before getting vaccinated to prevent post-vaccination symptoms?

Even though these medications may be taken to manage symptoms postvaccination, it is not recommended that such medication be regularly used before or during vaccination. However, in case these medications have been taken, vaccination can still be administered.

If needed to manage symptoms postvaccination, acetaminophen is preferred for use by older persons.

I already had COVID-19. Do I need to get the vaccine?

Even if you have already contracted COVID-19 in the past, you will still benefit from getting vaccinated because the immunity one develops after having both an infection and vaccination (known as hybrid immunity), have led to low rates of future infections and severe disease. This is especially the case with individuals who have hybrid immunity with an infection from a more recent Omicron strain.

It is recommended that for individuals who have not started or completed their primary series doses, they wait eight weeks from the positive test or symptom onset before getting vaccinated. For individuals who have completed their primary series, it is recommended they wait six months from the time of the previous infection to obtain their next vaccine dose.

There are no safety concerns with receiving vaccination after a recent infection, which has been found to be well tolerated; however, the reason for the time intervals is due to the understanding that an individual's resulting immune response is higher when there is a longer time between an infection and vaccination.

Even if hybrid immunity was already obtained from prior vaccination and infection, an individual's protection against infection eventually decreases over time. This is one of the reasons why doses are being recommended if people have not been vaccinated against or experienced a recent COVID-19 infection in the last six months.

Can I get the influenza vaccine and COVID-19 vaccine at the same time?

Not only the influenza vaccine, but COVID-19 vaccines may also be given at the same time, or any time before or after other vaccines (e.g., respiratory syncytial virus, pneumococcal and shingles).

Please speak with your health care provider regarding other vaccines that are recommended for you.

For more information on recommended vaccines for older adults, please see page 19.



Questions Specific to Older Adults

I'm an older adult. Should I get a COVID-19 vaccine?

Older adults have been found to be greatly impacted by COVID-19 infections, with adults 60 years and older making up 70 per cent of COVID-19 hospitalizations and 92 per cent of COVID-19 cases deceased in Canada.

The COVID-19 vaccines that have been approved in Canada for use in older Canadians have been found to be both extremely safe and effective.

There are many benefits associated with receiving the COVID-19 vaccine — they will lower your risk of getting sick if you are exposed to the virus and reduce risks of severe effects (e.g., hospitalizations, deaths). Receiving the COVID-19 vaccines will also protect those around you that may also be at risk of getting seriously ill. The Public Health Agency of Canada and Canada's medical and nursing associations recommend that all older Canadians get vaccinated when they are able to do so.

Vaccines are especially important with the current variants of SARS-CoV-2 being better able to avoid antibodies from vaccines and previous infection. Since the fall of 2023,

new formulations of COVID-19 vaccine have become available that are targeting these variants and are expected to provide better protection against these variants compared to currently available vaccines.

Are the COVID-19 vaccines effective and safe in older adults?

Yes, the Pfizer-BioNTech,
Moderna and Novavax vaccine
trials enrolled sizable numbers
of older adults in their original
vaccine trials to establish that
their COVID-19 vaccines are both
safe and effective.

While the overall efficacy of the Pfizer-BioNTech, Moderna and Novavax vaccines vary at preventing laboratory-confirmed COVID-19 illness in people, their efficacy in preventing hospitalization and death has been found to be the highest for individuals fully vaccinated in the clinical trials.

The updated XBB.1.5-containing COVID-19 vaccines are expected to perform better against the current strains compared to previously available COVID-19 vaccines. Already, data from animal and/or human trials demonstrated that the new

Moderna, Novavax and Pfizer-BioNTech vaccines developed robust immune responses against SARS-CoV-2 XBB*
Omicron virus strains.

Comparing differing efficacy rates between vaccine trials is not recommended because each trial has slightly different efficacy endpoints so these cannot be equally compared to each other. In addition, the clinical trials related to different COVID-19 vaccines were done in different countries at different times during the pandemic, and the amount of COVID-19 as well as the number and type of variants that were circulating during these trials could have impacted their efficacy results. What is important to remember is that all of the currently available vaccines are very effective in preventing severe illness, hospitalizations and COVID-19-related deaths.

However, regardless of vaccination, due to the uncertainties regarding COVID-19 and the length of protection from recommended vaccines and previous infection, we should not stop other important public health measures to prevent the spread of COVID-19. Mask wearing in public, physical distancing, frequent hand washing and avoiding crowded settings remain important strategies.

Which COVID-19 vaccines should older adults take and how far apart?

Older adults are recommended to receive the updated XBB.1.5containing mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna).

These vaccines are expected to provide a better immune response against the current circulating COVID-19 strains compared to the earlier COVID-19 vaccines, and will also improve protection against infection, symptomatic and severe disease that might have been reduced since a person's last vaccination or infection.

mRNA vaccines (Pfizer-BioNTech and Moderna) remain the preferred COVID-19 vaccines, with the original Nuvaxovid™ vaccine (Novavax) recommended to be used for those who are unwilling or unable to receive the mRNA vaccines. The recently approved Nuvaxovid™ XBB.1.5 (Novavax) COVID-19 vaccine is currently under review by NACI so that they can provide further guidance on how to best use this vaccine.

For individuals who have never received any doses of COVID-19 vaccines (have not started primary series doses) are recommended to receive one dose of the XBB.1.5-containing mRNA COVID-19 vaccine. If they had a recent COVID-19 infection, vaccination may be delayed by eight weeks.

For individuals who have started their primary series doses, but only received one dose of an earlier COVID-19 vaccine, are recommended to complete the series by receiving one dose of the XBB.1.5-containing mRNA vaccines. This dose can be received if it has been at least eight weeks since receiving the previous COVID-19 vaccination or infection.

For individuals who have completed their primary series doses (at least two doses of earlier COVID-19 vaccines) are recommended to receive a dose of the XBB.1.5-containing mRNA COVID-19 vaccine. This dose can be received if it has been at least six months since receiving the previous COVID-19 vaccination or infection.

UPDATE: Starting in the spring of 2024, NACI recommends older Canadians, individuals who are immunocompromised, adult residents of long-term care homes and other congregate living settings for older adults may receive an additional dose of XBB.1.5-containing mRNA COVID-19 vaccine. This additional dose can be received if it has been at least six months since receiving the previous COVID-19 vaccination or infection.

How Many Dose(s) of non-XBB.1.5-containing COVID-19 Vaccines Have You Received?	How Many Dose(s) of the XBB.1.5-containing mRNA COVID-19 Vaccines are Recommended?*	When to Receive the Recommended Dose?
0	1	Can receive it now Consider waiting for 8 weeks, if experienced a recent COVID-19 infection
1	1	8 weeks from the previous COVID-19 vaccination or infection
2 or More	1	6 months from the previous COVID-19 vaccination or infection**

^{*} Either Comirnaty® Omicron XBB.1.5 (Pfizer-BioNTech) or Spikevax® XBB.1.5 (Moderna).

^{**} A shorter interval (e.g., three months to <six months) has not been shown to pose a safety risk.

What are the side effects of the COVID-19 vaccines in older adults?

Vaccine side effects mean the body's immune system is kicking in and getting ready to recognize and fight off the virus if it ever encounters it in the future.

The side effects associated with COVID-19 vaccines are usually mild and no different in older adults than in the rest of the population.

What is most reassuring is that no clear pattern of serious or unexpected adverse events have occurred among the hundreds of millions of older adults who have been vaccinated against COVID-19 thus far.

Across the XBB.1.5-containing COVID-19 vaccines, common side effects may include pain where you were injected, tiredness, headache, nausea, muscle ache, and a fever. These side effects can last for a day or two, and rarely more than a few days.

Vaccine side effects are typically a sign that your immune system is doing exactly what it is supposed to do: working and building up your immunity to protect you from what you are being vaccinated against.

In fact, as older adults tend to have weaker immune systems than younger people, they appear to develop side effects at a lower rate, but are still achieving the same level of immunity or protection that younger adults are achieving with these vaccines.

You can have an allergic reaction to any medicine or food. It is possible that some people are allergic to an ingredient in the COVID-19 vaccines, but it is important to remember these allergic reactions are relatively rare. It is recommended that if you have allergies, including severe allergies that require you to carry an EpiPen, you should discuss the vaccine with your doctor who can assess your risk and provide more information about how to get vaccinated safely.

I am caring for an older adult that does not want to get the vaccine. How can I convince them that it is safe?

You can show an older adult COVID-19 Q&As such as this one or any of the links below that answer questions specifically related to older adults.

Also emphasize to the older adult in your life that COVID-19 is a serious illness and that 92 per cent of Canada's COVID-19 deaths have been among older Canadians 60 years of age and older.

It is understandable that older adults may be wary of the COVID-19 vaccine, but knowing the facts that any potential risks of side effects related to getting the vaccine are likely far better than the risk of dying from COVID-19 should provide them reassurance, especially when hundreds of millions of older people around the world have safely received the COVID-19 vaccine so far.



Questions for Specific Population Groups

Should older adults with health conditions get the COVID-19 vaccine?

Studies have shown that not only do adults with health conditions have a higher risk for severe outcomes from COVID-19, but the risk increases with the number of conditions.

For these reasons, vaccination is particularly important for the conditions listed below. If you have at least one of the following medical conditions (as noted by Canada's Public Health Agency of Canada), please speak with your health care provider regarding vaccination:

- Cancer
- Cerebrovascular disease
- Chronic kidney disease
- Certain chronic liver diseases
- Certain chronic lung diseases
- Cystic fibrosis
- Diabetes mellitus, type 1 and type 2
- Disabilities
- Heart conditions
- HIV infection
- Certain mental health disorders
- Obesity
- Primary immunodeficiency diseases
- Smoking, current or former
- Solid organ or blood stem cell transplant
- Tuberculosis
- Use of corticosteroids or other immunosuppressive medication

Is it safe to get the COVID-19 vaccine in older adults with health conditions?

Generally, it is safe for individuals with health conditions to get the COVID-19 vaccines.

However, it has been noted that those with either bleeding disorders or receiving blood thinner medications should inform their health care providers, in order to avoid the risk of bleeding, bruising or developing a haematoma (pooling of blood under the skin) following vaccination. It is also advised that adults who have any health condition or are taking medication notify their health care provider to avoid any side effects and ensure proper use of the vaccines.

Should someone with allergies get the COVID-19 vaccine?

Individuals with allergies whether related or not to the COVID-19 vaccine should discuss with their health care provider about getting the COVID-19 vaccine. For individuals who are advised to take the COVID-19 vaccine, the length of time observed after vaccination may vary depending on the type of allergy (15 to at least 30 minutes).

Even for individuals who had a mild to moderate allergic reaction to a previous dose of COVID-19 vaccine are advised to discuss this further with their health care provider, as they may be able to be receive another dose.

Is it safe to get the COVID-19 vaccine in older adults who are immunocompromised?

Immunocompromised patients, or those with weakened immune systems, tend to be at increased risk from becoming seriously ill and dying from COVID-19.

This can include older persons living with cancer, HIV, those who are transplant recipients, or are taking steroids or other medicines to treat certain medical conditions, called immunosuppressants, that lower the body's ability to fight some infections.

Because of their increased risk of becoming seriously ill and dying from COVID-19 infections, immunocompromised people should receive the COVID-19 vaccines if there are no absolute contraindications. As none of the currently approved vaccines include live virus, there is no risk of getting infected with the actual virus when getting vaccinated.

The need for COVID-19 vaccines by adults who are immunocompromised is clearly highlighted as they are recommended to receive two to three doses, four to eight weeks apart, for their primary series. Other adults are only recommended to receive one to two doses, eight weeks apart for their primary series. Please see table below for a summary of NACI recommendations for individuals who are immunocompromised.

Overall, for older Canadians with well-controlled immune disorders, medical experts emphasize that the positive benefits of the COVID-19 vaccines almost always outweigh any risks, and immunization is recommended.

Furthermore, it is always good to check for the latest information and advice around the safety and effectiveness of these vaccines with your doctor who knows your overall medical situation well.



Summary of NACI Recommendations for Immunocompromised Individuals

How Many Dose(s) of non-XBB.1.5-containing COVID-19 Vaccines Have You Received?	How Many Dose(s) of the XBB.1.5-containing mRNA COVID-19 Vaccines are Recommended?*	When to Receive the Recommended Dose(s)?
0	2	Can receive it now Consider waiting for 4 to 8 weeks, if experienced a recent COVID-19 infection Second dose to be given 4 to 8 weeks from the previous COVID-19 vaccination or infection
1	2	4 to 8 weeks from the previous COVID-19 vaccination or infection
2	1	4 to 8 weeks from the previous COVID-19 vaccination or infection
3 or more doses	1	6 months from the previous COVID-19 vaccination or infection**

^{*} Either Comirnaty® Omicron XBB.1.5 (Pfizer-BioNTech) or Spikevax® XBB.1.5 (Moderna).

UPDATE: Starting in the spring of 2024, NACI recommends individuals who are immunocompromised may receive an additional dose of XBB.1.5-containing mRNA COVID-19 vaccine. This additional dose can be received if it has been at least six months since receiving the previous COVID-19 vaccination or infection.

^{**} A shorter interval (e.g., three months to <six months) has not been shown to pose a safety risk.

Is it safe and recommended for older persons living with dementia to get the COVID-19 vaccine?

Age is the greatest risk factor for having dementia. People living with dementia often live with at least one other chronic condition and have been shown to be at much greater risk, compared to people without dementia, of getting infected, seriously ill and dying from COVID-19.

People living with dementia are more likely to have problems remembering and understanding recommended public health measures, such as physical distancing and wearing a mask in the presence of others, which significantly increases their risk of getting infected from COVID-19. This is why the Public Health Agency of Canada, Canada's medical and nursing associations, and the Alzheimer Society of Canada all recommend that all older Canadians, including those living with dementia, get vaccinated when they are able to do so.

There is some concern that some of the limited side effects associated with COVID-19 vaccines, like a sore arm, headache, muscle aches, fatigue, fever or diarrhea that can last for a few days may cause some increased confusion in a person living with dementia, but these post-vaccination side effects can usually be well-managed with acetaminophen or other treatments.

Millions of older persons around the world living with dementia have now safely received their COVID-19 vaccines and medical experts continue to emphasize that the positive benefits of the COVID-19 vaccines almost always outweigh any risks, with immunization especially recommended for people living with dementia.

I am a member of a racialized community and am hesitant to get the COVID-19 vaccine. How do I know it's safe for me?

It is understandable for racialized individuals, particularly Black and Indigenous Canadians, to be hesitant to get the vaccine due to systemic racism and historical mistrust of the Canadian health care system. However, Canadians of colour have been disproportionally affected by COVID-19 due to social, economic and health disparities, and getting the vaccine can provide them with the greatest level of protection from this virus.

Furthermore, Pfizer-BioNTech and Moderna have said the efficacy of their vaccines has been consistent across age, race and ethnicity, and gender demographics.

Debunking Myths About Covid-19 Vaccines

Does getting the vaccine mean that I will get COVID-19?

The COVID-19 vaccines that are currently available to Canadians cannot and will not give you COVID-19. All vaccines basically carry a recipe card that your body then uses to make just the small piece of harmless spike protein that is similar to the protein that exists on the actual COVID-19 virus, which helps your body recognize and fight the virus.

The COVID-19 vaccine does not actually contain the COVID-19 virus, so you cannot get COVID-19 from the vaccine. The synthetic DNA and mRNA that is central to the COVID-19 vaccines also breaks down quickly once it enters your body.

The COVID-19 vaccine will not make a nasopharyngeal (nasal) PCR test or Rapid Antigen Test (RAT) positive. If you test positive for COVID-19 on a RAT or PCR test, this means you have a COVID-19 infection, and it is unrelated to the vaccine.

I heard the materials in the vaccine are harmful. Is that true?

As noted earlier in this pamphlet, both the Pfizer-BioNTech and Moderna vaccines contain mRNA, whereas the Novavax vaccine contains SARS-CoV-2 recombinant spike protein and the adjuvant Matrix-M. Other ingredients in the approved COVID-19 vaccines are normal vaccine ingredients, such as fats, salts and a small amount of sugar. The vaccines do not include live virus and will not interact with our DNA.

All of the approved COVID-19 vaccines do not include any gelatin or animal materials. The Pfizer-BioNTech, Moderna and Novavax vaccines were not developed using fetal cell lines. It is important to note that none of the vaccines contain any fetal tissues or cells. The currently approved vaccines do not contain common allergens such as latex and food proteins (e.g., eggs, gluten, nut products or byproducts). The vaccines do not contain any material such as metals, implants, microchips or tracking devices.

I heard that individuals may get myocarditis/pericarditis after getting the COVID-19 vaccine. Is that true?

There is a very rare risk of individuals getting myocarditis (inflammation or swelling/redness of the heart muscle) and/or pericarditis (inflammation or swelling/redness of the lining outside the heart) through the available COVID-19 vaccines. The symptoms for most people resolve quickly through standard treatment and rest. Also, it has been found for both Pfizer-BioNTech and Moderna vaccines that these cases occurred particularly in adolescents and young adults. It is important to consider that myocarditis can even be result of COVID-19 infections.

Individuals who experienced myocarditis or pericarditis from a previous COVID-19 vaccine, may still receive another dose of the vaccine after first discussing this further with their health care providers.



Other Questions

How many older adults have been vaccinated in Canada?

As of the beginning of December 2023, 94 per cent of Canadians aged 60 years and older (not including Alberta) have received at least one dose of the COVID-19 vaccine. However, only 38 per cent of older Canadians have received the XBB.1.5-containing mRNA COVID-19 vaccine. This indicates most older adults in Canada are potentially eligible to receive the XBB.1.5-containing mRNA COVID-19 vaccines. This vaccine is expected to provide a better immune response against the current circulating COVID-19 strains, and also improve protection against infection, symptomatic and severe disease that might have been reduced since a person's last vaccination or infection.

How can I get a record of my COVID-19 vaccination history?

There are different ways you can get a record of your COVID-19 vaccination history. The online method includes the following instructions:

- Click on the following website link: https://www.canada.ca/en/public- health/services/diseases/coronavirus- disease-covid-19/vaccines/vaccine-proof.html.
- 2. Click on your province/territory box.
- 3. Click on the green box to visit the jurisdictional website.
- 4. Provide the needed information to obtain your COVID-19 proof of vaccination.


The telephone method includes the following instructions:

- Contact your primary health care provider as they should have a record of your COVID-19 vaccinations.
- If you are not able to confirm your vaccination history, ask your health care provider for other ways to try to determine this.

Will we have to continue getting a vaccine dose every three to six months?

Currently, there is uncertainty surrounding the annual pattern of COVID-19 infection, duration of immune protection from vaccines and/or infections, and the impact of future vaccines. As more research and data is released on these topics, NACI will provide Canadians with further recommendations on the interval between vaccine doses.

However, individuals should not wait on these decisions and act now on receiving vaccines.



There are five other vaccines approved and/or recommended for older adults in Canada, including:

Vaccine-Preventable Diseases	Duration of Vaccine Dose(s)
Influenza (flu)	One dose every year
Respiratory syncytial virus (RSV)	One dose
Pneumococcal disease (pneumonia)	One dose
Shingles	Two doses
Tetanus and diphtheria	One dose every 10 years

Most recommended vaccines can be given at the same time. Speak with your health care provider regarding staying up to date with your recommended vaccines.

To learn more about these vaccinepreventable diseases, national vaccine recommendations, costs and availability, please click on the following pamphlet link:

A Guide to Vaccines for Older
 Canadians pamphlet



Additional Helpful Resources

- World Health Organization COVID-19 vaccines and vaccine safety
- Public Health Agency of Canada COVID-19: Resources for seniors and their caregivers
- Unambiguous Science
- Johns Hopkins Medicine COVID-19 Vaccines: Myth Versus Fact

To learn more about the NIA visit our website at www.NIAgeing.ca and follow us on Twitter @NIAgeing